With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Join Drs. Prystowsky and Wilber as they discuss the results of pivotal cardiac resynchronization therapy trials in heart failure and their potential impact on the current treatment paradigm and guidelines.
Join Drs. Marchlinski, Bax, and Estes for a discussion on recent CRT-D trials, the impact of therapy in early-stage HF patients, and how LVEF, QRS duration, and NYHA class may guide treatment.
Advances have improved the ability to diagnose, prevent, and treat cardiac arrhythmias and associated conditions. Learn about ongoing improvements in arrhythmia management from a stellar Mayo Clinic faculty.
Join Drs. Fonarow, Gold, and Klein as they discuss recent clinical trial data in cardiac resynchronization therapy and left ventricular reverse remodeling in early-stage heart failure patients.
Join Drs. Prystowsky and Estes as they discuss risk stratification of patients with hypertrophic cardiomyopathy and strategies for implementing implantable device therapy.
Recently reported and new trials of antiplatelet therapy continue to redefine optimal management strategies for patients with atherothrombotic disease and patients with atrial fibrillation. Drs. Harrington, Angiolillo, Bhatt, Connolly, Mehta, and Simon discuss guidelines? recommendations for the use of antiplatelet therapies and the potential impact of emerging data regarding currently used and novel antiplatelet agents.
A high-risk patient for stroke, stent thrombosis, and bleeding presents a difficult but not unusual challenge. Drs. Lopes, Granger, and Alexander discuss how to balance the risks.
When is an effective, inexpensive, generic drug a liability? Such is the case for warfarin when reliable monitoring is either not available or untrustworthy. In many areas of the world, including rural areas of the United States and Latin America, eligible patients go untreated and are at risk for stroke. What does the future hold? Join Drs. Garcia, Carvalho, Granger, and Alexander for a discussion.
Atrial fibrillation affects nearly 7 million people in the United States and Europe. Please join Drs. Breithardt, Connolly, Crijns, Kirchhof, and Naccarelli for a discussion on strategies to improve outcomes in patients with AF.
Atrial fibrillation is associated with a high risk for stroke, myocardial infarction, heart failure, and death. How does blockade of the renin-angiotensin system affect patient outcomes? Join our international panel of experts, Drs Camm, Connolly, Crijns, and Granger, as they discuss the ESC 09 hotline results of the ACTIVE-I trial.
Read Dr. Jonathan Piccini's review of prevention of stroke in AF and how the newly released results of clinical trials of novel antithrombotic agents will reduce the risk for stroke. Then listen to our international panel of experts, Drs. Camm, Granger, Prystowsky, and Yusuf, as they give their take on new data released at ESC 2009.
Dr. Ileana Piņa discusses the design and outcomes of the MADIT-CRT trial with Drs. Moss and Estes, and how these new data may benefit patients with heart failure.
Evidence-based therapies, both pharmacologic and devices are well documented in published guidelines, but are they followed and implemented in practice? Is there a treatment gap? Is it all about education or the lack thereof? Drs. Yancy, Abraham, and Pfeffer confer on evidence from recent registries and trials.
Join our international panel of experts, Drs. Lip, Halperin, Weitz, Ezekowitz, Wallentin, and Connolly as they present late-breaking results of the RE-LY trial.
AF is sometimes considered a benign or nuisance condition. However, it is vital that it is recognized as a harbinger of underlying cardiovascular disease, and that it is diagnosed early and treated appropriately. Join Drs. Kirchhof, Dorian, Marrouche, and Steg as they discuss strategies to reduce the complications of AF.
Does early intervention with CRT-D slow the progression of heart failure? Watch as Dr. David Cannom interviews Drs. Camm, Hlatky, Klein, Moss and Page, and gets their expert opinions on late-breaking clinical trial data released at ESC 09 and how it will affect patient care.
The ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation were published in 2006. Since this publication, new data and treatment options have been developed. Join Drs. Prystowsky, Hohnloser, and Kowey, as they discuss these new data and strategies for implementation in clinical practice.
Hypertension plays a key role in the pathogenesis of atrial fibrillation. Join our expert panel, Drs. Agabiti-Rosei, Allessie, Crijns, Israel, and Weber for a discussion of the current data and treatment options for optimal management and improving outcomes in hypertensive patients with AF.
Join Prof. Santini and Drs. Gimbel and Sommer as they discuss the outstanding challenges surrounding the safety of MRI in patients with implantable cardiac pacing devices and highlight emerging strategies and technological advances that may help increase access to diagnostic care for patients.
Do we have enough data to suggest that MRI in pacemaker patients is safe? Join Dr. Roger Luechinger as he discusses safety concerns and novel approaches to overcome some of the existing limitations associated with imaging this population of patients.
Dr. Jeroen Bax, on the cusp of publishing a landmark paper to validate the role of MIBG imaging in risk stratifying patients with heart failure, provides a snapshot of his study in this interview from Europace 2009.
Dr. Ileana Piņa discusses the design and outcomes of the MADIT-CRT trial with Drs. Moss and Estes, and how these new data may benefit patients with heart failure.
Does early intervention with CRT-D slow the progression of heart failure? Watch as Dr. David Cannom interviews Drs. Camm, Hlatky, Klein, Moss and Page, and gets their expert opinions on late-breaking clinical trial data released at ESC 09 and how it will affect patient care.
A high-risk patient for stroke, stent thrombosis, and bleeding presents a difficult but not unusual challenge. Drs. Lopes, Granger, and Alexander discuss how to balance the risks.
When is an effective, inexpensive, generic drug a liability? Such is the case for warfarin when reliable monitoring is either not available or untrustworthy. In many areas of the world, including rural areas of the United States and Latin America, eligible patients go untreated and are at risk for stroke. What does the future hold? Join Drs. Garcia, Carvalho, Granger, and Alexander for a discussion.
Join Drs. Prystowsky and Wilber as they discuss the results of pivotal cardiac resynchronization therapy trials in heart failure and their potential impact on the current treatment paradigm and guidelines.
Join Drs. Marchlinski, Bax, and Estes for a discussion on recent CRT-D trials, the impact of therapy in early-stage HF patients, and how LVEF, QRS duration, and NYHA class may guide treatment.
Advances have improved the ability to diagnose, prevent, and treat cardiac arrhythmias and associated conditions. Learn about ongoing improvements in arrhythmia management from a stellar Mayo Clinic faculty.